Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) just unveiled an update.
China Resources Pharmaceutical Group Ltd. has announced the signing of a new Sales Framework Agreement with CR Healthcare, effective from January 1, 2026, to December 31, 2028. This agreement, which involves connected transactions due to the relationship between the companies, requires approval from independent shareholders as the applicable percentage ratios exceed 5%. An Extraordinary General Meeting (EGM) will be convened to seek this approval, and a circular detailing the agreement will be dispatched to shareholders.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
Average Trading Volume: 14,581,121
Technical Sentiment Signal: Sell
Current Market Cap: HK$28.96B
Find detailed analytics on 3320 stock on TipRanks’ Stock Analysis page.